Apogee Therapeutics, Inc. cotiza a 135.07 USD y tiene una capitalización bursátil de $10.2B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a mo…
| Periodo | 2026-11 |
|---|---|
| Real | — |
| Estimado | $-1.21 |
| Sorpresa | — |
| Métrica | APGE | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | — | -40.4% | — |
| ROA | -27.3% | -32.0% | +4.7% |
| Current Ratio | 26.57 | 2.84 | +23.73 |
| Debt / Equity | — | 0.28 | — |